Posted by Michael Wonder on 14 Feb 2023
Camurus withdraws variation application for CAM2038 to include chronic pain
13 February 2023 - Camurus announced today that it has notified the EMA of its decision to withdraw the Type II variation application for CAM2038 to include treatment of chronic pain in patients with opioid dependence.
The decision is based on Camurus’ assessment of the request from EMA’s CHMP for additional clinical data to support the proposed extended indication for CAM2038 (Buvidal).
